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Abstract
Purpose
The majority of prostate cancers are detected in men ages 65 and older, resulting in an increased
probability that these patients have prosthetic devices. Hip prostheses can pose a challenge when
creating a radiation therapy treatment plan for prostate cancer patients. The purpose of this study
is to compare two planning techniques that treat the target volume while avoiding irradiation
through these prostheses.
Methods
This retrospective study obtained previously treated patient data from the center’s treatment
planning system. Patients who were treated for prostate cancer and had one or two hip
prostheses were included in this study. Two plans were created for each patient, one which
utilized avoidance sectors around the prostheses, and one which utilized Varian’s Eclipse tool
“avoidance structures in optimization”. Prescriptions and optimization parameters were kept
constant between the two plans in an effort to observe the potential dosimetric differences
between the two planning techniques.
Results
It is observed that the mean bladder and rectum doses were decreased by using the avoidance
structure technique as compared to the avoidance sector optimization. The average difference in
mean rectum doses between the two plans was 497.3 cGy. For the mean bladder doses, the
average difference was 128.9 cGy. Additionally, the global maximum dose was observed to be
lower on average for the avoidance sector plans when compared to the alternative plan. An
average decrease of 2.23% was calculated. Tests on the conformity index of the treatment plans
yielded no significant difference between the two planning strategies.
Conclusion
The results of this study indicate that there is a dosimetric benefit to the use of avoidance
structures compare to avoidance sectors with respect to the mean bladder, mean rectum, and
global maximum doses. Additional studies with a larger data set that also takes into account
organ at risk volumes are required to further assess the impact of the new Varian Eclipse
optimization technique.
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Introduction
Prostate cancer is the most prevalent cancer among men. Approximately 12.5 percent of
men will be diagnosed with prostate cancer at some point during their lifetime. 1 Most prostate
cancers are detected in men 65 years and older, with the median age being 67. Due to increasing
Prostate-Specific Antigen (PSA) testing and life expectancy, more elderly men are being
diagnosed with prostate cancer. Men of African descent are at an increased risk of the disease.
In the United States, African Americans are more likely to be diagnosed with prostate cancer and
2.5 times more likely to die of the disease.2 Prostate cancer is highly curable. Most men with
prostate cancer will not die of their disease, but rather die with prostate cancer. The vast majority
of patients at diagnosis have a slow growing tumor that may take years to expand beyond the
prostate and potentially become a threat to their well-being. According to The National Cancer
Institute (NCI), the projected number of new cases in 2021 is 248,530. With its incidence rate
being so high, it is still the fifth leading cause of death worldwide. The NCI states, “The 5-year
relative survival rate for men diagnosed in the United States from 2010 to 2016 with local or
regional disease was greater than 99%, and the rate for distant disease was 30%; a 98% survival
rate was observed for all stages combined.” 3
This cancer forms in tissues of the prostate. The prostate is a walnut sized (20-30cc)
exocrine gland in the male reproductive system. It is found below the bladder and anterior to the
rectum. It sits between the bladder and the rectum and surrounds the urethra, the hollow tube
through which urine flows. The prostate consists of four anatomical zones: the peripheral,
central, transitional, and the anterior fibromuscular. Approximately 70% of prostate cancers are
found in the peripheral zone. 3 The prostate aids in the production of a fluid that makes up semen,
along with sperm cells from the testicles and fluids from other glands. 4 Semen is the milky fluid
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that nourishes, carries, and protects the sperm that are produced in the testicles. 5 The muscles of
the prostate also ensure that the semen is forcefully pressed into the urethra and then expelled
outwards during ejaculation.
Prostate cancer is staged pathologically and clinically using the Gleason scoring system.
Prostate-specific antigen is a protein produced by cells of the prostate gland. Typically, a PSA
level of 4.0 ng/mL and lower is considered normal. The National Cancer Institute approximates
15% of men with a PSA level less than 4.0 ng/mL will go on to develop prostate cancer in their
lifetime. PSA testing significantly improved prostate cancer survival rates due to earlier
detection of disease, allowing for resection and local treatment prior to metastasis. The American
Cancer Society recommends PSA testing for average risk men starting at age 50, African
Americans at age 45, and at age 40 for high-risk men with an early age first-degree relative. 2
Results from a biopsy are given in the form of a Gleason Score. Gleason Scores range from 2-10
that results from two summed grades within the tumor. The higher the score, the more likely the
cancer will spread. Grade 1 corresponds to well-differentiated, low grade dysplastic tissue, while
Grade 5 corresponds to the most abnormal, dysplastic tissue. The Gleason score is then used to
categorize cancer into low-grade (<6), intermediate grade (7) and high-grade (8–10) disease. 2
There are several treatment options for those with prostate cancer. Active surveillance is
available for patients with low grade disease. The cancer is closely monitored with biopsies and
PSA tests. Treatment may be considered if the cancer grows. Watchful waiting is an option for
patients who are expected to live for 10 year or less.6 Tests are not completed but the oncologist
may treat any symptoms that develop. Patients may elect to have a radical prostatectomy, where
the prostate and surrounding capsule, seminal vesicles, ampulla, and vas deferens are completely
removed. Radiation therapy can be done using external beam radiation (EBRT) or
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brachytherapy. Radiation can be used as a definitive treatment of localized disease, an adjuvant
treatment following a radical prostatectomy, salvage treatment for disease recurrence, and for
palliative disease. Intensity Modulated Radiation Therapy (IMRT), and more specifically
Volumetric Modulated Arc Therapy (VMAT), is now the standard of care when it comes to
radiation treatment of prostate cancer. VMAT is an inverse planning technique that adds the
aspect of gantry rotation to IMRT. VMAT provides improved conformality, homogeneity, organ
at risk (OAR) sparing, and improved delivery efficiency compared to static-gantry IMRT. 7 Plans
typically consists of two full, 360-dgree arcs utilizing 6 MV photons. If pelvic nodes are treated,
four arcs are often utilized. Hormone therapy, or androgen suppression therapy, can be used to
reduce testosterone in the patient and prevent the cancer to grow. Chemotherapy is often used if
the cancer has spread outside the prostate gland.
Simulation is an important step in radiation therapy planning. Often three gold fiducials
are placed in the prostate approximately a week prior to the simulation to help with alignment for
treatments. Patients are asked to have a full bladder and an empty rectum for their scan. A
comfortably full bladder helps push the small bowel out of the treatment area. Patients are asked
to replicate this every day for treatment as well. Typically, 18-24 ounces of water an hour before
the scan will achieve this. Enemas are typically used the night or morning before the simulation,
but patients aren’t expected to do an enema prior to each treatment. Contrast is used occasionally
to delineate small bowel or bladder. Patients are immobilized with a VacLok™ for their legs and
have their hands on their chest.
Hip replacements are becoming more prevalent each year. It has been projected that hip
replacements may increase by 34% in 2020, to 498,000 replacements; by 129% in 2030, to
850,000 replacements a year .8 This surgery is used to relieve pain from damaged or diseased hip
5

joints, improve the way the hip joint works or just to help you move better and improve your
quality of life. Hip replacement surgery, sometimes referred to as total hip arthroplasty, is a
surgical procedure that removes damaged bone and cartilage from the hip joint and replaces them
with prosthetic parts, typically plastic, ceramic, or metal. Most metals used are titanium alloys,
stainless steel, special high-strength alloys, alumina, zirconia, and zirconia toughened alumina. 9
These metals have a high Z number which alters the dose distribution and create inhomogeneity
in the surrounding areas of the body with low Z numbers (Figure 1). High-Z materials have a
higher stopping power for ionizing radiation than soft tissue. The high-density material adds
complications in terms of attenuation, scatter, and dosimetric uncertainty. 10 The dose attenuation
can range from 10% to 64% depending on the energy of the photon beam and the composition of
the hip prosthesis. Backscatter is also a concern at the bone-high-density interface, as the energy
and atomic number of the material increases, the backscatter factor increases. 7 Traditionally,
radiation therapy beams are designed such that they avoid passing through these prosthetic
materials.11,12 The American Association of Physicists in Medicine Task Group 63 recommend
that planners avoid orienting the beam through the prosthesis due to uncertainties in dose
calculations with metallic heterogeneities.13
Eclipse™ is the treatment planning system (TPS) by Varian Medical Systems. VMAT
avoidance sectors are regions along the arc rotation through which the treatment planner has
required no dose be delivered. Avoidance sectors block the whole radiation plane rather than
individual pixels within that plane (Figure 2). There is a maximum of two avoidance sectors for
each field arc. The minimum length for an avoidance sector is 15 degrees and the distance
between consecutive sectors must be greater than 15 degrees. Many studies on the use of
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avoidance sectors for prostheses have been completed for various types of cancer, as it is
currently the standard of practice.
The Eclipse avoidance structure tool gives planners the option to block radiation
completely from entering and/or exiting a contoured structure. It achieves this by blocking the
radiation pixel-by-pixel in a fluence plane (Figure 2). The Varian Eclipse Photon and Electron
Algorithm Reference Guide states, “The avoidance structure is then projected onto the fluence
plane, and if the radiation through a certain fluence pixel hits the avoidance structure before or
after hitting the target, the radiation through this fluence pixel is blocked.” When using “Entry”,
all control points where the OAR or structure that needs to be avoided is between the radiation
source and target. When using “Entry+Exit”, the decrease in dose is accomplished in all control
points where the OAR or the structure to be avoided is visible. There is little research done on
using avoidance structures with no entry and/or exit dose.
The objective of this study will be a comparison of using avoidance sectors and
avoidance structures during IMRT optimization for pelvic irradiation for eleven previously
treated prostate cancer patients with hip prosthetics. For this study, patients will receive a total
dose of 70 Gy in 28 fractions. 100% of the prescription will cover 98% of the PTV. This study
will be comparing the mean bladder and rectum doses between the avoidance sector and
avoidance structure plans. The researcher theorizes the mean bladder and rectum doses will be
lower in the plans utilizing avoidance structures compares to avoidance sectors. This study will
also compare the conformity index score between the two planning strategies. The conformity
index is defined as the ratio between the volume receiving ≥95% of the prescribed dose and the
volume receiving >95%. A conformity index of unity indicates high planning target volume
coverage and minimal irradiation dose to surrounding organs. The researcher hypothesizes that
7

utilizing an avoidance structure will result in a greater (lower) conformity index score. Finally,
this study will analyze the effect the different planning strategies have on the global maximum
dose point of the treatment plan.
Null Hypothesis 1 (H1:o): There is not a significant difference in the mean bladder and
rectum doses between the plans optimized using avoidance structures compared to those
optimized using avoidance sectors.
Alternative Hypothesis 1 (H1:a): The use of avoidance structures compared to avoidance
sectors will result in significantly lower mean bladder and rectum doses.
Null Hypothesis 2 (H2:o): There is not a significant difference in the global maximum
dose between the plans optimized using avoidance structures compared to those optimized using
avoidance sectors.
Alternative Hypothesis 2 (H2:a): The use of avoidance structures compared to avoidance
sectors will result in a lower global maximum dose.
Null Hypothesis 3 (H3:o): There is not a significant difference in the conformity index
between the plans optimized using avoidance structures compared to those optimized using
avoidance sectors.
Alternative Hypothesis 3 (H3:a): The use of avoidance structures compared to avoidance
sectors will result in an improved conformity index score.
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Research Design/Methodology
Patient Selection

The institution’s treatment planning database was retrospectively searched for patients
treated for prostate cancer during the previous eight-year period. Each treatment planning scan
of that cohort of patients was then reviewed for the presence of unilateral or bilateral hip
prostheses. The resulting eleven patients were then selected for this study. Only two of the
study subjects had bilateral protheses, with the remaining having a single prosthetic device,
either a full hip replacement or titanium femoral rod. Of the 11 study patients, 8 of those had
pelvic lymph node radiation to 4500 cGy, followed by a sequential boost to the prostate and
proximal seminal vesicles to a total dose of 7920 cGy. Three patients were only treated to the
prostate and seminal vesicles. The prescription for two of those patients was 250 cGy x 28
fractions, while the third was 200 cGy x 40 fractions. All patients were previously treated with
VMAT and avoidance sectors of varying arc length. Avoidance segment arc lengths ranged
from 73-degrees to 108-degrees, with a mean length of 90.4-degrees. All study subjects’ data
sets were run through a DICOM cleaning tool to remove any identifying information. Cleaned
data was re-imported into the treatment planning system and each subject was assigned a unique
identifier.
Treatment Planning

All of the study subjects had been simulated on a Siemens SOMATON Definition AS CT
scanner, in the supine position with a VacLok™ inferior to the buttocks and formed around the
legs and feet. It was decided that the focus of this study would be the treatment of the prostate
and seminal vesicles only. Therefore, although the eight patients with pelvic lymph node
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treatment are included in this research, treatment plans were only created for the planning target
volume (PTV) that included the prostate and seminal vesicles. In order to analyze a direct
comparison of the avoidance structures and avoidance sectors techniques, the patients’ previous
treatment plans were disregarded and each dataset subject to new optimization and calculation
with the institution’s current default Eclipse algorithms.
At the time of planning, the default calculation algorithm was Varian’s Acuros XB
(AXB), Version 15.606. AXB is a grid-based linear Boltzmann transport equation algorithm. It
was the first commercial algorithm to accurately model the sharp dose gradients found at the
interfaces of high and low Z materials.14 The accuracy of AXB during VMAT and in the
presence of high-Z materials as compared to Monte Carlo simulations was assessed by Ojala et
al. 14 Hybrid VMAT techniques consisting of partial arcs avoiding the high-Z materials
combined with static beams traversing those materials showed very good agreement with full
Monte Carlo simulations. As such, it may be possible to eliminate any type of avoidance due to
metallic objects during VMAT optimization with AXB. However, the accuracy of the
institution’s calculations of dose traversing such high-Z materials with this algorithm has yet to
be validated in the clinic. Furthermore, not all facilities have access to Acuros XB or similar
algorithms, and this research may prove beneficial to treatment planners utilizing Varian’s
Analytical Anisotropic Algorithm (AAA).
Each patient was initially optimized using one avoidance segment per arc, except for the
subjects with bilateral hip replacement, which requires two avoidance segments per arc. Two
full arcs, clockwise and counter-clockwise, were created for each plan, with collimator angles
optimized for target coverage. 6 MV photons from the clinic’s Varian Edge Linear Accelerator
were used for planning, as is standard within the department. Parameters were adjusted during
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the optimization process until the institution’s protocols for target coverage and organ at risk
(OAR) constraints were met. For the bladder, the volume receiving 70 Gy had to be less than
10%. Bladder volume receiving 64 Gy was must be less than 20%, V60 Gy less than 30%, and
V55 Gy less than 40%. The volume of rectum receiving 63 Gy had to be less than 10%. Further
rectum constraints were: V59Gy less than 20%, V55Gy less than 30%, and V51Gy less than
40%. The dose to 1cc for the femoral heads was less than 47 Gy. The mean dose of in the penile
bulb had to be below 44 Gy. The optimized plans were then calculated with the Acuros XB
algorithm. Plans were normalized such that 100% of the prescription dose covered 98% of the
PTV and the goal for the maximum dose to 0.03cc of the PTV was to be less than 110% of the
prescription dose. The final metric was sometimes difficult to achieve due to the nature of
treatment plans with limiting angles for irradiation. The resultant DVH was compared against
the clinical protocol. When all constraints were met, and/or approved by the clinic’s medical
physicist, the plan was considered satisfactory.
Approved avoidance sector plans were then optimized without the skip angles.
Optimization parameters were kept the same as the parameters that resulted in the accepted
avoidance sector plan. However, in place of avoidance sectors, the new plans used the high-Z
material as an avoidance structure with no entrance dose allowed through those structures. All
remaining variables were kept constant between the two types of plans. Optimized plans were
once again calculated with Acuros XB and the resultant DVH analyzed.
The DVH for the two plans of each study subject were compared for differences in the
calculated mean bladder and rectum doses. Additionally, the conformity index of the PTV for
each plan was evaluated.
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Analysis

Parametric tests were used to compare the variables between the avoidance sector and
avoidance structure plans. IBM SPSS version 20 software was used for statistical analysis. A
paired samples t test was used to compare the means of the bladder, rectum, and conformity
index for the two types of generated plans. The purpose of the test is to determine whether there
is statistical evidence that the mean difference between paired observations is significantly
different from zero. A p value of < 0.05 represented statistical significance.
The test statistic for the Paired Samples t Test, denoted t, follows the same formula as the
one sample t test.

𝑡=

𝑥𝑑𝑖𝑓𝑓 − 0
𝑆

where

𝑆 =

𝑆
√𝑛

where
𝑥𝑑𝑖𝑓𝑓 = Sample mean of the differences
n = Sample size (i.e., number of observations)
𝑆

= Sample standard deviation of the differences

𝑆 = = Estimated standard error of the mean (s/√𝑛)
The calculated t value is then compared to the critical t value with df = n - 1 from the t
distribution table for a chosen confidence level. If the calculated t value is greater than the
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critical t value, the null hypothesis is rejected. The means are then considered to be significantly
different.15
Nonparametrical tests were also performed on the data in an effort to confirm the results
from the paired samples t test. Both the Wilcoxon signed test and Wilcoxon signed rank test
were run using the SPSS software. These tests compare the averages of the two dependent
variations of the planning data and assesses for statistical significance. The Wilcoxon signed test
is an alternative to the Paired Samples t test. The test is a repeated measures test of dependency.
However, this test pools all differences, ranks them and applies a negative sign to all the ranks
where the difference between the two observations is negative. This is called the signed rank.
Whereas the paired samples t-test tests whether the average difference between two observations
is 0 the Wilcoxon test tests whether the difference between two observations has a mean signed
rank of 0. Thus, it is much more robust against outliers and heavy tail distributions. As a result,
it is the best test to compare mean scores when the dependent variable is not normally
distributed. 16
Results
Eleven patients were selected for this study. Each patient had two plans created, for a
total of 22 treatment plans. PTV volumes ranged from 106 cc to 310.7 cc. The average PTV
volume was 156.4 cc, with the median volume measuring 134.2 cc (Table I). The global
maximum point dose as reported by Eclipse ranged from 107.3% to 115.5% for all 22 plans.
Rectum

Patient rectum volumes ranged from 25.7 cc to 117.3 cc, with the average rectum volume
measuring 61.7 cc (Table I). Median rectal volume for the study was 55.4 cc. The greatest mean
13

rectum doses were 4950.3 cGy and 3528.3 cGy for the avoidance sector and avoidance structure
population, respectively (Table II). Avoidance sector plans had an average rectum mean dose of
3107.0 cGy, with a standard deviation of 932.0 cGy (Table III). The avoidance structure plans
had an average rectum mean dose of 2609.7 cGy, with a standard deviation of 487.5cGy.
The average difference in the mean rectum doses was 497.3 cGy, with a standard
deviation of 695.3 cGy (Table IV). A t value (10 degrees of freedom) of 2.372 was calculated
with a significance level (p) of 0.039, indicating that there exists a significant difference between
the voidance sector and avoidance structure plans. There were two study subjects who had
differences of greater than 1000 cGy in mean rectum dose between the avoidance sector and
avoidance structure plans. The differences were 1893.3 cGy and 1884.4 cGy. These values are
the contributing factors for the large standard deviation and were calculated for the two bilateral
hip replacement patients. The smallest difference in mean rectum dose was 92.9 cGy.
The nonparametric Wilcoxon Signed Rank Test calculated a p value of 0.003. This result
agrees with the Paired Samples t Test, showing even greater significance in the differences
between the sector and structure plans.
Bladder

Patients had been simulated with a comfortably full bladder. Prior to their appointment,
they are given instructions on bladder filling. There are varying degrees of compliance with
these instructions. Bladder volumes for the subject patients ranged from 87.1 cc to 394.9 cc,
with an average volume of 201.2 cc (Table I). The median bladder volume was observed to be
167.2 cc. Avoidance sector plans calculated an average mean dose to the bladder of 2282.4 cGy,

14

with a standard deviation of 781.4 cGy, while the avoidance structure plans had an average mean
dose of 2153.5 cGy, with a standard deviation of 721.3 cGy (Table III).
The paired differences tests resulted in an average difference of 128.9 cGy in the mean
bladder dose between the avoidance sector and structure plans (Table IV). The standard
deviation was 178.5 cGy. The t (df10) value for this observation was 2.395, with p value of
0.038. This also indicates there is a significant difference in the mean bladder doses between the
two planning strategies.
The nonparametric Wilcoxon Signed Rank Test calculated a p value of 0.021. This result
agrees with the Paired Samples t Test, indicating that there exists a significance in the differences
between the sector and structure plans.
Conformity Index

The conformity index is a measure of how closely the prescription isodose line matches
the volume it is intended to target. The mean conformity index for the avoidance sector plans
was 1.128, with a standard deviation of 0.097 (Table III). The avoidance structure plans had a
mean conformity index of 1.077, with a standard deviation of 0.022. Conformity index ranged
from 1.06 to 1.39 for the avoidance structure plans, and from 1.03 to 1.10 for the avoidance
sector plans (Table II). The least conformal plans were those for the bilateral hip replacement
patients, with conformity indices of 1.39 and 1.21.
The mean difference in conformity index was 0.051, with a standard deviation of 0.102
(Table IV). A t value (df10) of 1.663 was calculated, with a level of significance of 0.127. This
p value indicated that there is not a significant difference between the conformity index of the
two types of plans.
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Similar results were observed with the Wilcoxon Signed Rank Test. A p value of 0.063
was calculated and the researcher can conclude that there is no significant difference between
plans with respect to conformity index.
Global Maximum Point Dose

The global maximum dose point reported by Eclipse is a measure of the greatest dose to a
single voxel in the calculation grid. The global maximum dose ranged from 108.5% to 115.5%
for the plans using avoidance sectors. These values ranged from 107.3% to 114.5% for the
avoidance structure plans (Table II).
The mean global maximum dose for the avoidance sector plans was 112.6%, with a
standard deviation of 2.62% (Table III). For the structure plans, the mean global maximum dose
was 110.3%, with a standard deviation of 2.53%. The mean difference between the paired
samples was calculated to be 2.24%, with a standard deviation of 1.73% (Table IV). A t (df10)
value of 4.28 was observed with a p value of 0.002. The difference between the global
maximum doses for the two types of plans is therefore considered to be significant.
The Wilcoxon Signed Rank Test calculated a p value of 0.003. This result agrees with the
Paired Samples t Test.
Study Limitations
The facility’s incidence of pelvic irradiation of patients with metallic implants was very
limited. As a result, the number of study patients (11), was also small. A larger number of data
points would yield more accurate statistical analysis. Another potential impact on the
observations of this research is the variability in the volumes of the bladder and rectum. The
treatment planning system has an easier time managing the mean doses for larger volumes, as the
16

optimizer has an increased number of possibilities to come to a solution. The correlation of these
organ at risk volumes with the statistical tests may be the subject of future investigation.
Additionally, the study may want to discern between unilateral and bilateral prostheses, if the
appropriate number of subjects can be screened.
Conclusion
The Varian Eclipse optimization tool employing avoidance structures allows for VMAT
treatments of pelvic patients with metallic implants while not irradiation through the high-density
object. It provides additional beamlets of the radiation beam to target the treatment volume
when compared to utilizing avoidance sectors.
Utilizing zero entry dose for the metallic implants yielded plans which had a statistically
significant decrease in mean bladder and rectum doses, when compared to the avoidance sector
technique that has been historically endorsed. The greatest improvement in mean dose was
observed in the patients who had bilateral hip replacements, suggesting that this technique may
provide the most improvement for those patients.
Avoidance structure plans also resulted in statistically significant lower global maximum
doses but did not show improvement in the conformity index of the PTV.
These finding have led the researcher to reject the null hypothesis, H1:0, which states
there is not a significant relationship between the decrease in mean bladder and rectum doses and
the use of avoidance sectors. Similarly, the null hypothesis, H2:0, is rejected. There is a
significant relationship between the use of avoidance structures and lower global maximum
doses. The null hypothesis, H3:0, is, however, accepted. The data does not support the
argument that the use of avoidance sectors results in plans with a superior conformity index.
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Tables and Figures
Table I. Organ at risk and Planning Target Volumes (PTV)

Patient

Rectum Volume (cc)

Bladder Volume (cc)

PTV (cc)

1

25.7

87.1

182.1

2

63.4

376.9

160.3

3

52.6

142.0

134.2

4

93.3

195.3

126.3

5

47

108.6

106

6

67.5

167.2

310.7

7

67.1

289.5

113.2

8

37.3

151.8

110.3

9

117.3

394.9

147.4

10

52.5

131.7

222.7

11

55.4

168.7

106.7

Figure 1. Axial image of patient with bilateral hip replacement
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a

b

Figure 2. Beam’s Eye View (BEV) image of Multileaf Collimators during VMAT Arc (a) Open MLC during
avoidance sector arc. No radiation is delivered to the PTV (red) as the arc passes by the prostheses (orange). (b)
MLCs and collimator jaws close to prevent entrance dose through the prothesis, while delivering dose to the PTV.
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Table II. DVH results of Avoidance Sector and Avoidance Structure Plans

Patient ID

Plan Type

Rectum
(mean dose)
cGy

Bladder
(mean dose)
cGy

Conformity
Index

Global Maximum
Dose (%)

Patient 1

Avoidance Sector
Avoidance Structure

2352.60
2259.70

2585.60
2541.80

1.08
1.08

110.70
109.60

Patient 2

Avoidance Sector
Avoidance Structure

3307.80
3144.50

2246.90
2198.60

1.12
1.08

111.20
108.30

Patient 3

Avoidance Sector
Avoidance Structure

2073.70
1975.90

2705.60
2341.00

1.10
1.09

111.60
109.00

Patient 4

Avoidance Sector
Avoidance Structure

4950.30
3056.40

2217.60
1699.50

1.39
1.08

115.10
109.30

Patient 5

Avoidance Sector
Avoidance Structure

2336.20
2221.70

1493.90
1478.60

1.06
1.06

109.00
108.00

Patient 6

Avoidance Sector
Avoidance Structure

3204.20
2798.20

3663.10
3425.20

1.09
1.09

115.20
113.50

Patient 7

Avoidance Sector
Avoidance Structure

2374.90
2220.60

1572.60
1588.50

1.05
1.05

108.50
107.30

Patient 8

Avoidance Sector
Avoidance Structure

2425.50
2285.50

2050.00
2034.90

1.08
1.10

112.20
111.50

Patient 9

Avoidance Sector
Avoidance Structure

4292.20
2407.80

880.00
876.30

1.21
1.03

114.40
109.30

Patient 10

Avoidance Sector
Avoidance Structure

3873.40
3528.30

2578.70
2587.30

1.12
1.09

115.50
114.50

Patient 11

Avoidance Sector
Avoidance Structure

2986.40
2808.30

3112.10
2916.80

1.11
1.10

115.30
113.80
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Table III. Paired Samples Statistics
Mean
Pair 1

Pair 2

Pair 3

Pair 4

Std. Deviation

N

Std. Error Mean

Rectum_Sector

3107.0182

11

931.96080

280.99675

Rectum_Structure

2609.7182

11

487.47991

146.98072

Bladder_Sector

2282.3727

11

781.36418

235.59016

Bladder_Structure

2153.5000

11

721.25822

217.46754

Conformity_Sector

1.1282

11

.09662

.02913

Conformity_Structure

1.0773

11

.02195

.00662

GlobalMax_Sector

112.609

11

2.6163

.7888

GlobalMax_Structure

110.373

11

2.5295

.7627

Table IV. Paired Samples Test – Paired Differences
Paired Differences
95% Confidence Interval of
Std

Pair 1

Rectum_Sector -

.

Mean

Deviation

.

695 30359

128 87273

.

.05091

497 30000

the Difference

.

Std Error
Mean

.

209 64192

178 45537

.

.10153

Lower

.

30 18869

53 80632

.

8 98478

.03061

- 01730

.5230

1 0711

Upper

t

.

2 372

.

964 41131

.

248 76067

.

2 395

.

.11912

1 663

df

.

Sig (2-tailed)

.

10

.039

.

10

.038

.

10

.127

.

10

.002

Rectum_Structure
Pair 2

Bladder_Sector Bladder_Structure

Pair 3

Conformity_Sector Conformity_Structure

Pair 4

GlobalMax_Sector -

.

2 2364

.

1 7345

.

.

3 4016

4 276

GlobalMax_Structure
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Mean Dose (cGy)
Figure 3. Comparison of Mean Rectum Doses. Avoidance Sector vs Avoidance Structure
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Mean Dose (cGy)
Figure 4. Comparison of Mean Bladder Doses. Avoidance Sector vs Avoidance Structure
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Mean Dose (%)
Figure 5. Comparison of Global Maximum Doses. Avoidance Sector vs Avoidance Structure
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